Logo

SRTS

Sensus Healthcare, Inc.

SRTS

Sensus Healthcare, Inc. • NASDAQ
$4.12 ▲ 0.24% (+0.01)
Market Cap $67.67 M
52w High $9.30
52w Low $3.03
Dividend Yield 0%
P/E -22.89
Volume 15.90K
Outstanding Shares 16.43M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $6.884M ▼ $5.282M ▲ $-943K ▲ -13.698% ▲ $-0.058 ▲ $621.999K ▲
Q2-2025 $7.315M ▼ $4.846M ▼ $-1.037M ▲ -14.176% ▲ $-0.064 ▲ $-1.785M ▲
Q1-2025 $8.344M ▼ $7M ▲ $-2.572M ▼ -30.825% ▼ $-0.16 ▼ $-2.501M ▼
Q4-2024 $13.066M ▲ $5.38M ▲ $1.546M ▲ 11.832% ▼ $0.095 ▲ $1.86M ▲
Q3-2024 $8.839M $3.745M $1.215M 13.746% $0.074 $1.597M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $24.453M ▲ $58.295M ▼ $7.101M ▲ $51.194M ▼
Q2-2025 $22.162M ▲ $58.852M ▼ $6.788M ▼ $52.064M ▼
Q1-2025 $19.072M ▼ $60.21M ▼ $7.176M ▲ $53.034M ▼
Q4-2024 $22.056M ▼ $62.165M ▲ $6.338M ▲ $55.827M ▲
Q3-2024 $22.558M $59.858M $5.727M $54.131M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $0 ▲ $0 ▼ $0 ▲ $0 $2.291M ▼ $0 ▼
Q2-2025 $-1.037M ▲ $3.117M ▲ $-27K ▼ $0 ▲ $3.09M ▲ $3.09M ▲
Q1-2025 $-2.572M ▼ $-2.677M ▼ $-7K ▼ $-300K ▼ $-2.984M ▼ $-2.684M ▼
Q4-2024 $1.546M ▲ $-827K ▼ $297K ▲ $28K ▲ $-502K ▼ $-530K ▼
Q3-2024 $1.215M $3.953M $-337K $-30K $3.586M $3.616M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Product
Product
 $10.00M ▲$10.00M ▲$10.00M ▲$0 ▼
Product Revenue
Product Revenue
 $0 ▲$0 ▲$0 ▲$0 ▲
Service
Service
 $0 ▲$0 ▲$0 ▲$0 ▲
Service Revenue
Service Revenue
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Revenue has grown from a very small base and now appears to be on a more stable footing, with the business generally profitable over the last several years after an earlier period of losses. Profitability looks decent for a company of this size, but the earnings pattern has been bumpy, with one standout year and then a step down to more normal levels. That suggests results can be sensitive to one‑time events, order timing, or macro conditions. Overall, the income statement shows a company that has proven it can make money, but not yet with the smooth, predictable trend seen in more mature medical device peers.

Balance Sheet

Balance Sheet The balance sheet looks conservative and relatively clean. The company carries essentially no financial debt, which reduces refinancing and interest‑rate risk and gives it more flexibility during weaker periods. Cash makes up a meaningful share of total assets, and both assets and equity have trended upward over the past few years, indicating gradual strengthening of the financial base. For a small med‑tech company, this is a fairly solid starting point, though it still lacks the scale and cushion of larger industry players.

Cash Flow

Cash Flow The cash‑flow data provided are very limited, which makes it hard to judge the true quality and consistency of cash generation. Historically, small device companies often see cash flows swing with large orders, inventory builds, and investments in sales and R&D, and Sensus is likely no exception. The absence of clear free‑cash‑flow strength means investors would want to pay close attention to future filings for proof that reported profits reliably convert into cash and that growth can be funded without taking on debt or frequent equity raises.

Competitive Edge

Competitive Edge Sensus operates in a focused niche: non‑invasive treatment of non‑melanoma skin cancers and keloids in dermatology settings. Its image‑guided superficial radiation systems are tailored for office use, which sets them apart from more generalized oncology equipment and surgical approaches. The company benefits from proprietary technology, dedicated reimbursement codes, and a creative revenue‑sharing model that lowers upfront cost for physicians and can create sticky, recurring relationships. At the same time, its niche focus and small size mean it is exposed to reimbursement changes, competitive innovation, and the pace at which dermatologists embrace non‑surgical options.

Innovation and R&D

Innovation and R&D Innovation is a clear strength. The core SRT platform, especially the image‑guided SRT‑100 Vision, combines targeted low‑energy radiation with built‑in imaging, delivering a differentiated, cosmetic‑friendly alternative to surgery. On top of this, Sensus is working on a needle‑free transdermal infusion system, a handheld ultrasound device, and the Sentinel software platform to tie hardware, workflow, and data together. These efforts, if successfully commercialized and approved where necessary, could deepen its ecosystem around dermatology practices and open adjacent revenue streams, though each carries regulatory, adoption, and execution risk typical for early‑stage med‑tech projects.

Summary

Sensus Healthcare presents as a small but focused medical device company with a proven, profitable niche in non‑invasive dermatologic treatments. Its income statement shows that it can generate earnings, but with some volatility that points to sensitivity to order flow and market conditions. The balance sheet is conservative, with no meaningful debt and a reasonable cash cushion, which partially offsets its small scale. The competitive position is built around proprietary SRT technology, favorable reimbursement, and an integrated service and software offering, but the company remains dependent on a relatively narrow clinical area and policy environment. Its active pipeline and software ambitions highlight meaningful upside potential alongside the usual risks of product development, regulation, and commercialization for a company of this size.

NEWS

November 14, 2025 · 8:00 AM UTC

Sensus Healthcare Expands Role of President Michael Sardano to Include Chief Commercial Officer

Read more

November 12, 2025 · 8:00 AM UTC

Sensus Healthcare Appoints Eric Sachetta to its Board of Directors

Read more

November 6, 2025 · 4:05 PM UTC

Sensus Healthcare Reports Third Quarter 2025 Financial Results

Read more

November 6, 2025 · 8:00 AM UTC

Sensus Healthcare Named to TIME's America's Growth Leaders of 2026

Read more

November 4, 2025 · 8:00 AM UTC

CMS Establishes Coding Validating Sensus SRT for Treating Non-Melanoma Skin Cancer

Read more